Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines

BACKGROUND: Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor and rapamycin analogue that is approved for treating advanced renal cell carcinoma (RCC). It is being actively evaluated in clinical trials for melanoma. The mTOR inhibitors are also immunosuppressants and are used clinical...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wang, Y, Wang, X-Y, Subjeck, J R, Shrikant, P A, Kim, H L
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2011
Gaiak:
Translational Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3049595/
https://ncbi.nlm.nih.gov/pubmed/21285988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.15
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak